Avandia: GlaxoSmithKline agrees to settle before FDA vote
Posted by: Stephen Leshner
July 14, 2010

   The move comes as the Food and Drug Administration votes today whether or not to withdraw Avandia from the market over its heart attack risks.

   GlaxoSmithKline will settle about ten-thousand lawsuits for an average payout of $46,000 apiece.

   Avandia's U.S. sales comprised only a tiny one-and-a-half percent of the British drugmaker's 2009 sales.

   Its withdrawal from the market could spur more lawsuits, however.

   The FDA could choose to keep Avandia on the market but beef up its black-box warning about the risk of heart attacks.

   The other option would be to further restrict Avandia's use.

  Glaxo moved quickly after two U.S. Senators ratcheted up the pressure yesterday by releasing documents underscoring safety concerns with the drugs.

   The documents showed Glaxo had tried to brush off scientific concerns about the increased risk of heart attack in users.

   The FDA is also under pressure of its own, coming from consumer groups eager to test the Obama administration's promises of a more activist watchdog role for the agency.

   If you or someone close to you has been injured as a result of taking Avandia, please call Steve Leshner.

Permalink

Zimmer Duron Cup Hip Replacement Cases
Posted by: Stephen Leshner
June 24, 2010

   The U.S. Judicial Panel on Multidistrict Litigation has decided that all federal lawsuits involving the Zimmer Durom hip implants which involve allegations that the hip replacement device caused problems such as loosening of the hip joint and the need for additional surgery, should be consolidated for pretrial litigation in the U.S. District Court for the District of New Jersey.

   The Panel's order, issued June 9, 2010 will result in 45 Zimmer hip replacement lawsuits currently pending in seven different federal courts across the country being transferred to Judge Susan D. Wigenton in New Jersey. The Panel determined that the cases should be consolidated as part of a multidistrict litigation, or MDL, since they involve sufficiently common questions of fact. Since most of the cases were already pending in New Jersey federal court, the Panel determined that was the most reasonable location for centralization.

   The product liability claims involve allegations that problems with Zimmer Durom Cup hip implants were caused by defects in the design and manufacture of the components and due to Zimmer's failure to provide adequate warnings about the device.

   The Zimmer Durom Cup was first introduced in the United States in 2006, as a more advanced form of an artificial hip. The hip resurfacing system is designed out of a single piece of material and is supposed to avoid problems associated with traditional hip replacement components, such as instability, limited range of motion and wear of the bearing.

   Shortly after Zimmer introduced the Durom Cup in the United States, concerns emerged about a high number of hip replacement failures involving the hip implant, where the component loosened and required revision surgery. A temporary Zimmer Durom Cup recall was issued in July 2008, so that revisions could be made to the product's warnings and instructions to ensure that doctors were properly trained on the surgical techniques needed to implant the artificial hip correctly.

   Approximately 12,000 individuals had the Zimmer Durom Cup system implanted in their hip between 2006 and 2008. While Zimmer's own estimates suggested that some doctors have experienced failure rates as high as 5.7%, the plaintiffs claim that about 14% of those who have had the Durom Cup hip replacement implanted have required hip revision surgery.

   As of the end of last year, more than 500 adverse event reports have been filed with the FDA regarding Zimmer Durom Cup problems and many experts anticipate that the rate of hip cup loosenings could increase as time passes after the surgery.

   Although there are only 45 currently pending federal lawsuits over problems with Zimmer Durom Cup hip implants, it is expected that the number of cases will increase in coming months.   Zimmer opposed centralization of the cases, arguing that the cases involve multiple individualized fact issues and that creation of an MDL might derail their attempts to reach Durom Cup settlements without the expenditure of substantial time and resources. The MDL Panel disagreed, indicating that centralization was appropriate to eliminate duplicative discovery, prevent inconsistent pretrial rulings on discovery and to conserve the resources of the parties, attorneys and the courts.

   "Centralization should pose no realistic obstacle to Zimmer's settlement efforts," wrote Judge John G Heyburn, Chairman of the Panel on Multidistrict Litigation, in the order. "Should the parties to one or more actions believe that early resolution through mediation or other means is possible, they are free to approach the transferee judge to adjust the pretrial schedule accordingly."

   While the pretrial management of the cases in an MDL is in many ways similar to how a class action lawsuit would be handled, each claim will still remain an individual lawsuit that would be returned back to the jurisdiction where it was originally filed for trial if it does not settle or otherwise resolve during pretrial litigation.

  Steve Leshner is currently handling a Zimmer Durom Cup case in Maricopa County Superior Court in Phoenix, Arizona, and successfully prevented the case from being transferred into the federal court MDL.  If you or someone you know has been injured as a result of a Zimmer Durom Cup hip implant, please call Steve Leshner for a free consultation to review your case.

Permalink

DePuy ASR Hip Replacements
Posted by: Stephen Leshner
June 24, 2010

    In March of this year, the New York Times published an article about the high early failure rate of DePuy's ASR hip replacement. Since that article was published, many more reports of failures of ASR hip replacements have been received by both DePuy and the United States Food and Drug Administration. In its article, the New York Times quoted orthopedic experts critical of the design of the ASR hip replacement. Experts were also critical of DePuy's failure to stop sales of the device sooner.

   The evidence suggeststhat that the DePuy ASR hip replacement was defectively designed, and that DePuy knew that their ASR hip replacements were failing at a higher than expected rate, yet  did not pass that information on to consumers or orthopaedic surgeons. As a result, a diagnosis that the ASR hip replacement implanted in patients failed were needlessly delayed as their physicians were unaware of the prevelance of other failures. During patients' surgeries to replace failed hip replacements, orthopedic surgeons discovered that the cup portion of the ASR hip replacement were extremely loose. The ASR hip replacement was designed so that a patient's bone grows into the back of the cup to secure it. However, loosening because of a lack of bone in-growth into the cup is the critical aspect of DePuy ASR hip replacement failures.

   If you or someone you know suffered from a DePuy ASR hip replacement failure, please call Steve Leshner for a free case review and consultation.  Several years ago, Steve Leshner successfully handled over 50 Sulzer Orthpaedic hip failure cases which were also caused by a manufacturing defect that prevented adequate lack of bone-ing growth, and the consequent loosening of the cup.

Permalink

FDA Refuses to Withdraw Zicam Recall
Posted by: Stephen Leshner
March 09, 2010

PDATE 1-Matrixx: FDA declines to withdraw warning letter

Tue Mar 9, 2010 6:27am EST

Stocks

Matrixx Initiatives MTXX.O $4.81 -0.06-1.23% 10:31am MST

* Says FDA reaffirms original position

Stocks | Regulatory News | Healthcare

* Co says evaluating options

March 9 (Reuters) - Matrixx Initiatives Inc (MTXX.O) said U.S. health regulators declined to withdraw the warning letter on the company's nasal versions of Zicam cold remedy.

Last June, the company voluntarily withdrew two of its existing Zicam products after the U.S. Food and Drug Administration issued a warning letter that the products could cause a loss of smell. [ID:nN24151638]

In October, the company had said that the FDA had indicated that it was unwilling to reverse its position.

In a regulatory filing with the U.S. Securities and Exchange Commission Tuesday, the company said it had filed in November a response to the warning letter but the FDA reaffirmed its original position.

Matrixx said it was evaluating its options.

Permalink

Matrixx Says FDA Won't Budge on Recalled Zicam Products
Posted by: euser
October 28, 2009

It looks like federal health regulators aren't backing down when it comes to recalled Zicam Nasal Cold Remedies. According to a Reuters report, Matrixx Initiatives Inc., the maker of Zicam products, said the Food & Drug Administration (FDA) is "unwilling to reverse its position regarding the warning letter" it issued over Zicam nasal remedies earlier this year.

In June, the FDA said it had received 130 reports of anosmia-loss of sense of smell-in people who had used the product. Following the FDA alert, Matrixx Initiatives recalled two of the products: Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Swabs. The company had already withdrawn Zicam Cold Remedy Swabs, Kids Size, the third product named by the FDA.

At the same time, the FDA issued a warning letter to Matrixx. In the letter, the FDA said Matrixx had failed to inform it of 800 anosmia reports linked to the recalled cold remedies. Matrixx has admitted that it did not pass along those reports to the FDA, but has maintained that its legal counsel advised it was not required to forward those reports to the agency. In the Warning Letter, the FDA warned the firm that the products cannot be marketed without agency approval and also stated that the three Zicam nasal remedies did not include adequate warnings about the risk of loss of sense of smell.

According to Reuters, Matrixx said in a regulatory filing with the Securities and Exchange Commission (SEC) that the FDA will not reverse its stance that the recalled Zicam products could not be marketed without agency approval. The filing said the company is currently evaluating its options. Matrixx also said it was reviewing the FDA's contention that it should have filed adverse event reports on several individual Zicam loss of smell cases, and that it would be responding soon.

Since the Zicam nasal cold remedy recall, Matrixx has been hit with several class action lawsuits filed on behalf of people who claim the products caused them to suffer anosmia. Earlier this month, the U.S. Judicial Panel on Multidistrict Litigation consolidated the Zicam litigation for pretrial proceedings in the District of Arizona for coordinated handling.

According to Reuters, the recent SEC filing also disclosed that two shareholder derivative lawsuits were filed in September against current and former Matrixx officers related to the recall.

Permalink

U.S. Drug Watchdog Issues Zicam Warning
Posted by: euser
October 21, 2009

The US Drug Watchdog Calls Zicam Nasal Gel or Zicam Swabs a Looming Disaster that May Cause Loss of Taste or Smell

The US Drug Watchdog is doing everything possible to get the word out to all US citizens about recalled Zicam products. So what exactly did the FDA say about zicam Nasal Gel & zicam Cold Remedy Swabs in its recall? The U.S. Food and Drug Administration (FDA) has warned Matrixx Initiatives to stop selling three over-the-counter zicam products, marketed as cold remedies, after more than 130 people reported developing long-lasting or permanent loss of smell (called anosmia). The warning applies to: zicam Cold Remedy Nasal Gel, zicam Cold Remedy Nasal Swabs, and zicam Cold Remedy Swabs, Kids Size (a discontinued product).If a consumer has lost their sense of taste or smell after using a recalled Zicam product, please call the US Drug Watchdog at 866-714-6466, or contact the group via its web site at http://usdrugwatchdog.com/

(PRWEB) October 21, 2009 -- The US Drug Watchdog is urging all US Consumers to check to see if they have recalled Zicam products in their medicine cabinets. If they do, and there has been no loss of taste, or smell, throw the product away. If on the other hand a US consumer has lost their sense of taste or smell within the last three years, after using the recalled zicam products, please call the US Drug Watchdog immediately at 866-714-6466, or contact the group via its web site at http://usdrugwatchdog.com/

our worst case scenario is a consumer gets a cold, or the flu, goes to their medicine cabinet & uses a recalled Zicam product. The consumer uses a recalled product & then they lose their sense of taste or smell, because the Zicam recall notification was only on the news for one day (June 16th 2009).

there could be millions of US households that have recalled Zicam Cold Remedy Nasal Gel, or Zicam Cold remedy swabs in their medicine chests, that need to be thrown away. However, if you have lost your sense of taste or smell, do not throw the recalled product away-its evidence you will need.

our greatest fear is that with the cold & flu season already here, completely innocent consumers will use one of the recalled Zicam products and lose their sense of taste, or smell forever.

Please share this press release with everyone you know. Make sure these recalled Zicam products are not in your medicine cabinets at home.

we know of a young woman, who had a great job in the food & wine industry. She has lost her sense of taste & smell. She is now unemployed.

Why Should Every American Check Their Medicine Cabinets For Recalled Zicam Products?

According to the US Drug Watchdog, "our worst case scenario is a consumer gets a cold, or the flu, goes to their medicine cabinet & uses a recalled Zicam product. The consumer uses a recalled product & then they lose their sense of taste or smell, because the Zicam recall notification was only on the news for one day (June 16th 2009)." If a consumer lost their sense of taste or smell after using a recalled Zicam product, please call the US Drug Watchdog immediately at 866-714-6466, or contact the group via its web site at http://usdrugwatchdog.com/

How Many Americans Could Be Affected With The Recalled Zicam Products?

According to the US Drug Watchdog,"there could be millions of US households that have recalled Zicam Cold Remedy Nasal Gel, or Zicam Cold remedy swabs in their medicine chests, that need to be thrown away. However, if you have lost your sense of taste or smell, do not throw the recalled product away-its evidence you will need." For more information please contact the US Drug Watchdog at 866-7144-6466, or contact the group via its web site at http://usdrugwatchdog.com/

National Appeal: The US Drug Watchdog is asking every US citizen to share this press release with everyone they know. According to the group,"our greatest fear is that with the cold & flu season already here, completely innocent consumers will use one of the recalled Zicam products and lose their sense of taste, or smell forever." For more information please contact the US Drug Watchdog at 866-714-6466, or contact the group via its web site at http://usdrugwatchdog.com/

A Special Note From The US Drug Watchdog To All US Women & Mothers. "Please share this press release with everyone you know. Make sure these recalled Zicam products are not in your medicine cabinets at home." The group is saying, "we know of a young woman, who had a great job in the food & wine industry. She has lost her sense of taste & smell. She is now unemployed."

What products are affected by this warning?

FDA's action affects Zicam's three intranasal products that contain zinc. The three Zicam products claim to reduce the duration of the common cold and the severity of cold symptoms.

The products (listed with their size and product numbers) are

Zicam Cold Remedy Nasal Gel (15mL, NDC 62750-003-10) Zicam Cold Remedy Swabs (20 swabs, NDC 67250-003-20) Zicam Cold Remedy Swabs, Kids Size (20 swabs, NDC 67250-003-21)

Permalink

Zicam Litigation Update
Posted by: euser
September 18, 2009

The U.S. Judicial Panel on Multidistrict Litigation is scheduled to hear arguments next week over whether all federal Zicam lawsuits should be centralized and consolidated in one district as part of an MDL, or Multidistrict Litigation.

The hearing, which is scheduled for September 24 in Richmond, Va., will give plaintiffs and defendants a chance topresent oral arguments for or against the consolidation. There are currently at least 10 lawsuits over Zicam pending in 9 different federal district courts against Matrixx Initiatives, which manufactured the over-the-counter cold remedy that was recalled earlier this year amid concerns that it may cause users to suffer permanent loss of smell.

The FDA warned consumers to stop using Zicam nasal gel and swabs on June 15, after receiving more than 130 reports of users developing anosmia, a condition where they are unable to smell. Although Matrixx Initiatives has maintained that their product is safe and does not cause loss of smell problems, they have since disclosed that they were aware of another 800 reports of Zicam side effects that were never turned over to the FDA.

The Zicam lawsuit complaints contain similar allegations that zinc gluconate, the single active ingredient in Zicam Cold Remedy, is toxic to the tissue inside the nose and is responsible for causing damage to plaintiffs ability to smell, detect odors or taste. In addition to the damage this condition can cause to an individuals quality of life, it could also lead to life-threatening injuries if someone is unable to smell dangerous fumes, smoke or food that has gone rotten.

Zicam products were not regulated or approved by FDA because they were listed as homeopathic treatments using natural products. However, at the time of the FDA announcement, Matrixx Initiatives was warned that they would no longer be permitted to market the homeopathic products until they submit data establishing the safety and effectiveness for FDA review.

At least one plaintiff, Stefanie Riepe, who filed a Zicam lawsuit against Matrixx Initiatives in the Western District of Missouri, filed a motion asking that all federal cases involving similar injuries and allegations be consolidated into an MDL to avoid inconsistent pretrial rulings, repeat discovery on issues common to all cases and to serve the convenience of the parties, the witnesses and the court. The plaintiff requests that the cases be assigned to the Western District of Missouri, but the MDL Panel will determine where the cases are sent if they determine consolidation is appropriate.

If the cases are centralized, as new cases are filed in various federal courts by Zicam lawyers who are currently investigating potential claims, they will be transferred into the MDL for coordinated handling during pretrial proceedings. If the cases do not settle or otherwise resolve, they will ultimately be returned to the courts where they were filed for trials.

Permalink

Stephen I. Leshner, P.C. Files Complaint in Arizona for 117 Zicam Victims
Posted by: euser
June 23, 2009

As reported in the Arizona Republic, and many other news organizations, I filed suit in Maricopa County Superior Court, Phoenix, Arizona for 117 individuals who claim they lost their sense of smell (anosmia) as a result of taking Zicam.  If you or someone who know took Zicam, and suffered a loss of the sense of smell, please call me immediately.

Scottsdale-based maker of Zicam faces lawsuit

4 comments by Ken Alltucker - Jun. 22, 2009 04:54 PM
The Arizona Republic

In what could be the opening salvo in a new wave of lawsuits against the Scottsdale-based maker of Zicam, lawyers on Monday filed a lawsuit on behalf of 117 people who claim they have suffered loss of smell after using the popular nasal spray.

Among those suing Scottsdale-based Matrixx Initiatives Inc. include one dozen Phoenix-area residents as well as the chef of an upscale Las Vegas-area restaurant who no longer can smell or taste food.

Matrixx officials said Monday they had not seen the lawsuit filed in Maricopa County Superior Court, but a spokesman said the company believes that its nasal products are safe and do not cause loss of smell.   Company officials are bracing for additional lawsuits after the Food and Drug Administration last week issued a warning letter linking Zicam nasal gel and swabs to loss of smell. The company responded by voluntarily recalling its Zicam Cold Remedy nasal gels and swabs from retailers nationwide. The company has more than a dozen oral Zicam products that were not targeted by the FDA and remain in stores nationwide.

William Hemelt, Matrixx's acting president and chief operating officer, last week said the FDA's warning letter and following publicity "undoubtedly" leaves the company vulnerable to additional lawsuits.

Legal battles are nothing new for Matrixx. The company has already faced more than 400 lawsuits over the past decade from people who claimed that Zicam's Cold Remedy gel has caused anosmia, or loss of smell. In 2006, the company settled a batch of lawsuits with 340 plaintiffs for $12 million to avoid the legal cost of defending each individual lawsuit.

Among the plaintiffs in the lawsuit filed Monday include Richard Kennedy, 62, of Glendale. The retired Arizona Supreme Court research analyst said he used the Zicam gel about three to five times earlier this decade. He later noticed that be could not smell odors that his friends and family could. He was diagnosed with anosmia by an ear, nose and throat specialist.

"If I knew (loss of smell) was a potential side effect, I never would have taken it," Kennedy said.

Kennedy is represented by Phoenix attorney Stephen Leshner as well as a law firm based in Houston, Texas.

 

 

Permalink

Zicam
Posted by: euser
June 16, 2009

As reported in today's Wall Street Journal, the U.S. Food and Drug Administration (FDA) said that consumers need to stop using certain Zicam cold and allergy products because they can cause permanent loss of smell.

WASHINGTON (Dow Jones)--The U.S. Food and Drug Administration said Tuesday consumers need to stop using certain Zicam cold and allergy products because they can cause permanent loss of smell.

In a warning letter sent to Matrixx Initiatives Inc., Zicam's maker, the FDA said it "has concluded that these products may pose a serious risk to consumers who use them." The agency, which has recently stepped up its enforcement activities, said the products cannot be marketed unless Matrixx seeks FDA approval to sell the products.

Shares of Matrixx Initiatives Inc. (MTXX), maker of Zicam, dropped 68% to $6.26 in recent trading.

In a statement, Matrixx said it "believes the FDA action is unwarranted and is in the process of determining its response, which may include removing these products from the marketplace." However, the company said in a separate statement posted on Zicam's Web site that it would stop shipping the products and would reimbuse customers seeking a refund.

The company said it believes the affected products are safe and do not cause anosmia," or loss of smell. The Zicam intranasal products account for about 40% of the company's net sales, which totaled $111.63 million for the year that ended on March 31. Sales of over-the-counter cold and cough products total about $4 billion annually.

Zicam is sold over-the-counter, primarily as a cold and allergy remedy. The products are sold in various forms including intranasal products meant to be used in the nose.

The FDA said consumers should stop using the intranasal zinc-containing products, which are sold as Zicam Cold Remedy Nasal Gel and Zicam Cold Remedy Gel Swabs. The agency also said consumers should also stop using Zicam Cold Remedy Swabs, Kids Size, which the company is no longer selling. Agency officials said consumers could still have the children's-size product in their medicine cabinets.

The action doesn't affect other Zicam products, such as tablets, "rapid melts" and liquid forms.

FDA officials said they've received more than 130 reports from consumers about the loss of smell, but said they believe that Matrixx has received about 800 such reports, which have not all been reported to the agency. The FDA said the reports showed that many people who experienced a loss of smell said the condition occurred with the first dose while others reported a loss of the sense of smell after multiple uses of the products. The agency said the loss of smell can be long-lasting or permanent.

In 2006, Matrixx settled more than 300 lawsuits brought by consumers who alleged that Zicam zinc nasal gel damaged or destroyed their sense of smell.

Maxtrixx wasn't required to submit adverse events to the FDA until the end of 2007 when a law went into effect requiring over-the-counter supplement makers to report side effects to the FDA, an agency spokeswoman said.

If you or someone you know has taken Zicam, and suffered a loss of taste and smell, please call me for a free consultation.  I am handling these cases personally, and I will help you.  Since Matrixx is located in Phoenix, AZ, these cases will be litigated here. 

Permalink

Fentanyl Pain Patch
Posted by: euser
February 05, 2009

On December 31, 2008, Ortho-McNeil-Janssen Pharmaceuticals, Inc., a division of health care giant Johnson & Johnson, announced that it recalled two lots of 50 mcg Duragesic pain patches.  The patches were recalled because of cuts in the products that could potentially expose its users directly to fentanyl gel, causing a potentially fatal overdose. 

This recall is yet another product recall, as well as FDA Advisories involving fentanyl pain patches over the last several years.  If you or someone close to you has suffered personal injuries or death as a result of using any brand of fentanyl pain patch, please call me to discuss your options.

Permalink

Avandia
Posted by: euser
January 14, 2009

According to a recent study conducted by researchers at the Harvard Medical School, elderly people with diabetes who took Avandia (rosiglitazone) were more likely to develop congestive heart failure and die, than people who took Actos(pioglitazone).  Using a database of Medicare beneficiaries to track 28,361 patients over five years, half of whom took rosiglitazone, while the other half took pioglitazone, death rates were 15% higher in the patients who took rogiglitazone, and their congestive heart failure incidence was 13% higher.  According to Wolfgang C. Winkelmayer, Assistant Professor of Medicine at the Harvard Medical School, and an author of the observational study, "Rosiglitazone was associated with greater mortality".

Both the American Diabetes Association and the European Association for the Study of Diabetes have removed rosiglitazone from the list of recommended treatments for type 2 diabetes.  While sales of Avandia have fallen sharply, it remains on the market in the U.S.  Public Citizen has called for the U.S. Food and Drug Administration to ban the drug, claiming it causes liver failure, vision impairment, and other serious side effects, in addition to heart problems.

If you or a loved one has taken Avandia, and suffered serious medical complications, please call me to discuss your options.

Permalink

15 Passenger Vans
Posted by: euser
December 22, 2008

Fifteen passenger vans are commonly used by schools, day care centers, Scout troops, churches and hotels.  All American car makers build a version, and Ford sells the most.  There are over 500,000 of them on the road.  And they are probably the most dangerous vehicles on the road.  Since 1990, over 500 people have been killed or seriously injured in 15 passenger van rollovers.

The National Highway Traffic Safety Administration has warned, "The risk of rollover increases dramatically as the number of occupants increases", and found that with ten or more passengers, 85% of the crashes involved a rollover.  Unbelievably, the government doesn't require any rollover standards.

While these vehicles are inherently unsafe, they are "safer" with ten passengers or less, wearing seatbelts, seated closer to the front of the vehicle, and with properly inflated tires. 

 If you or someone close to you has died or been seriously injured in a 15 passenger van rollover, please call me to discuss the potential case.

Permalink

Yamaha Rhino ATV
Posted by: euser
September 23, 2008

 

Hundreds of people nationwide have filed lawsuits against the Yamaha Motor Corporation charging that the Yamaha Rhino is a dangerously unstable and defective all terrain vehicle (ATV).  The allegations are that the Yamaha Rhino ATV contains multiple design flaws causing it to be unstable and prone to tipping and rolling over, even when driven at slow speeds on flat surfaces.  The alleged defects include a top heavy design resulting in a high center of gravity and a dangerously narrow track width.

If you or someone you know has been seriously injured in a rollover event involving a Yamaha Rhino ATV, please call me to discuss a possible claim.

 

Permalink

Chantix
Posted by: Stephen Leshner
September 15, 2008

Chantix was approved as a smoking cessation aid in 2006 and has been prescribed to more than four million patients.  In November, 2007, the Food and Drug Administration (FDA) issued an Early Communication to the public and health care providers, announcing it was investigating reports of adverse events, which included behavior changes, agitation, depression and suicidal ideation and behavior.  The FDA reported more accounts of serious side effects in the fourth quarter of 2007 from Chantix than any other drug.

New research indicates a link between Chantix and suicide, homicidal thoughts, heart trouble, psychosis, heart trouble, diabetes, Steven-Johnson syndrome, and liver failure.  If you or someone you know have taken Chantix and experienced one or more of these serious side effects, please call me to discuss a potential claim.

Permalink

Accutane
Posted by: euser
August 13, 2008

Accutane is a severe acne treatment manufactured by Hoffman-LaRoche, Inc. which has been found to cause inflammatory bowel disorder, which also includes chronic inflammation of the intestinal tract.  If you or someone you know has been taking Accutane, and developed serious injuries to the colon and rectum as a result, please call, e-mail or write me to discuss your potential claim

Permalink

Mesothelioma
Posted by: euser
August 13, 2008

 

Mesothelioma is a form of cancer that is caused by exposure to asbestos.  Many people who develop mesothelioma have worked on jobs where they inhaled asbestos particles or have been exposed to asbestos dust and fibers.  For example, an auto mechanic who worked for many years installing brakes and clutches, and developed mesothelioma, would have a claim against the manufacturers, suppliers and sellers of brakes and clutches containing asbestos.  If you or someone you know has been diagnosed with mesothelioma, please call, e-mail or write me to discuss your potential claim.

 

Permalink